Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.80
CLDN's Cash to Debt is ranked lower than
60% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CLDN: 6.80 )
Ranked among companies with meaningful Cash to Debt only.
CLDN' s 10-Year Cash to Debt Range
Min: 6.8  Med: 9999.00 Max: No Debt
Current: 6.8
F-Score: 1
Z-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -68.88
CLDN's ROE (%) is ranked lower than
72% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CLDN: -68.88 )
Ranked among companies with meaningful ROE (%) only.
CLDN' s 10-Year ROE (%) Range
Min: -320.68  Med: -320.68 Max: -320.68
Current: -68.88
ROA (%) -58.68
CLDN's ROA (%) is ranked lower than
74% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CLDN: -58.68 )
Ranked among companies with meaningful ROA (%) only.
CLDN' s 10-Year ROA (%) Range
Min: -87.49  Med: -70.06 Max: -61.4
Current: -58.68
-87.49
-61.4
ROC (Joel Greenblatt) (%) -7303.77
CLDN's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CLDN: -7303.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25840.98  Med: -9317.21 Max: -6183.38
Current: -7303.77
-25840.98
-6183.38
» CLDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CLDN Guru Trades in

Q1 2014

CLDN Guru Trades in Q1 2014

Steven Cohen 34,821 sh (New)
» More
Q4 2014

CLDN Guru Trades in Q4 2014

Steven Cohen 7,400 sh (New)
Jim Simons 21,600 sh (New)
» More
Q1 2015

CLDN Guru Trades in Q1 2015

George Soros 120,000 sh (New)
Jim Simons 298,300 sh (+1281.02%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CLDN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.51
CLDN's P/B is ranked higher than
98% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CLDN: 0.51 )
Ranked among companies with meaningful P/B only.
CLDN' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 6.5
Current: 0.51
0
6.5
EV-to-EBIT 0.72
CLDN's EV-to-EBIT is ranked higher than
94% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. CLDN: 0.72 )
Ranked among companies with meaningful EV-to-EBIT only.
CLDN' s 10-Year EV-to-EBIT Range
Min: 0  Med: 0.00 Max: 0
Current: 0.72
Current Ratio 11.78
CLDN's Current Ratio is ranked higher than
80% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CLDN: 11.78 )
Ranked among companies with meaningful Current Ratio only.
CLDN' s 10-Year Current Ratio Range
Min: 2.83  Med: 13.33 Max: 19.55
Current: 11.78
2.83
19.55
Quick Ratio 11.78
CLDN's Quick Ratio is ranked higher than
80% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CLDN: 11.78 )
Ranked among companies with meaningful Quick Ratio only.
CLDN' s 10-Year Quick Ratio Range
Min: 2.83  Med: 13.33 Max: 19.55
Current: 11.78
2.83
19.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.53
CLDN's Price/Net Cash is ranked higher than
100% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. CLDN: 0.53 )
Ranked among companies with meaningful Price/Net Cash only.
CLDN' s 10-Year Price/Net Cash Range
Min: 2.42  Med: 6.26 Max: 8.13
Current: 0.53
2.42
8.13
Price/Net Current Asset Value 0.52
CLDN's Price/Net Current Asset Value is ranked higher than
100% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CLDN: 0.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLDN' s 10-Year Price/Net Current Asset Value Range
Min: 2.39  Med: 6.19 Max: 7.89
Current: 0.52
2.39
7.89
Price/Tangible Book 0.51
CLDN's Price/Tangible Book is ranked higher than
98% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CLDN: 0.51 )
Ranked among companies with meaningful Price/Tangible Book only.
CLDN' s 10-Year Price/Tangible Book Range
Min: 2.37  Med: 6.11 Max: 7.76
Current: 0.51
2.37
7.76
Earnings Yield (Greenblatt) (%) 138.88
CLDN's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CLDN: 138.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLDN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.9  Med: 0.00 Max: 829.5
Current: 138.88
-14.9
829.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:72C.Germany,
Celladon Corp was incorporated in California on December 21, 2000 and reincorporated in Delaware in April 2012. The Company is a clinical-stage biotechnology with industry expertise in the development of cardiovascular gene therapy. Its programs target sarco/endoplasmic reticulum Ca2+ -ATPase, or SERCA, enzymes, which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, which is a clinical syndrome characterized by poor heart function resulting in inadequate blood flow to meet the body's metabolic needs, as well as blood vessel health, diabetes and neurodegenerative diseases. SERCA2a, an enzyme that becomes deficient in patients with heart failure, was scientifically validated as a molecular target for heart failure in the 1990s and became a focus of internal discovery efforts for many large pharmaceutical companies. Its therapeutic portfolio includes both gene therapies and small molecule compounds targeting diseases characterized by SERCA enzyme deficiency. MYDICAR, its advanced product candidate, uses gene therapy to target SERCA2a. Its suppliers include Lonza and Novasep, for the manufacturing of its viral vectors and product candidates for clinical testing purposes. The Company expect to rely upon Lonza, Novasep, and/or other third parties to produce materials required for the commercial production of its product candidates and companion diagnostic. Its commercial strategy involving a progressive build out of commercial infrastructure in the United States covering key prescribers and centers of excellence is one that they can realistically pursue. The Company face potential competition from many different sources, including larger and funded pharmaceutical companies. Its competitors include Renova Therapeutics, NanoCor Therapeutics, Juventas Therapeutics, VentriNova and Beat BioTherapeutics. Biological products, including gene therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&C Act and the PHS Act and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. The Company requires to obtain FDA approval before clinical testing of a biological product begins, and each clinical trial protocol for a gene therapy product is reviewed by the FDA and, in some instances, the U.S. National Institutes of Health, or NIH, through its Recombinant DNA Advisory Committee, or RAC.
» More Articles for CLDN

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency o Jul 16 2015 
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 

More From Other Websites
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency... Jul 30 2015
Morgan & Morgan Reminds Investors That Class Action Lawsuits Have Been Filed Against Celladon... Jul 30 2015
LAWSUIT ALERT REMINDER: The Law Firm of Andrews & Springer LLC Announces That a Securities Fraud... Jul 27 2015
Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International,... Jul 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Jul 24 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celladon Corporation of Pendency of... Jul 20 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Reminds Investors With Losses In Celladon Corporation Of... Jul 17 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency... Jul 16 2015
TRADING ALERT: The Rosen Law Firm Reminds Celladon Corporation Investors of the Important Deadline... Jul 15 2015
IMPORTANT SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal... Jul 13 2015
Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders... Jul 13 2015
SECURITIES FRAUD ALERT: The Law Firm of Andrews & Springer LLC Announces That A Securities Fraud... Jul 13 2015
Stull, Stull & Brody Announces the Filing of a Class Action Suit on Behalf of Purchasers of... Jul 10 2015
INVESTOR ALERT: Investigation of Celladon Corp. Announced by Law Offices of Howard G. Smith Jul 08 2015
LAWSUIT ALERT: The Law Firm of Andrews & Springer LLC Announces That a Securities Fraud Class Action... Jul 08 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Celladon... Jul 07 2015
Robbins Arroyo LLP: Celladon Corporation (CLDN) Misled Shareholders According to a Recently Filed... Jul 07 2015
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Celladon Corporation -... Jul 07 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Celladon... Jul 06 2015
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Celladon... Jul 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK